Gossamer Bio regains full global rights to its PAH candidate after terminating its collaboration with Chiesi, complemented by balance-sheet restructuring. The FDA view of PROSERA as a review issue supports an NDA filing using PROSERA and TORREY data, with a potential Q3 2027 approval, contingent on acceptability. With about $57M in cash and meaningful debt reduction, the setup improves optionality for investors.
Gossamer Bio Inc.'s shares declined following disappointing topline results from their Phase 3 PROSERA trial of seralutinib for pulmonary arterial hypertension. Investors anticipated more favorable outcomes, making the market reaction particularly negative. This setback may impact the stock's performance in the near term as investors reassess the company's pipeline potential.
Gossamer Bio announced that its experimental drug failed to meet the main goals in a late-stage study focused on a serious lung and heart condition. This failure is likely to lead to negative investor sentiment as regulatory pathways may become uncertain, impacting future market performance.
